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Rationale: Accurate peri-operative risk prediction is an essential element of clinical practice. Various risk
stratiﬁcation tools for assessing patients’ risk of mortality or morbidity have been developed and applied
in clinical practice over the years. This review aims to outline essential characteristics (predictive
accuracy, objectivity, clinical utility) of currently available risk scoring tools for hip fracture patients.
Methods: We searched eight databases; AMED, CINHAL, Clinical Trials.gov, Cochrane, DARE, EMBASE,
MEDLINE and Web of Science for all relevant studies published until April 2015. We included published
English language observational studies that considered the predictive accuracy of risk stratiﬁcation tools
for patients with fragility hip fracture.
Results: After removal of duplicates, 15,620 studies were screened. Twenty-nine papers met the
inclusion criteria, evaluating 25 risk stratiﬁcation tools. Risk stratiﬁcation tools considered in more than
two studies were; ASA, CCI, E-PASS, NHFS and O-POSSUM. All tools were moderately accurate and
validated in multiple studies; however there are some limitations to consider. The E-PASS and
O-POSSUM are comprehensive but complex, and require intraoperative data making them a challenge
for use on patient bedside. The ASA, CCI and NHFS are simple, easy and inexpensive using routinely
available preoperative data. Contrary to the ASA and CCI which has subjective variables in addition to
other limitations, the NHFS variables are all objective.
Conclusion: In the search for a simple and inexpensive, easy to calculate, objective and accurate tool, the
NHFS may be the most appropriate of the currently available scores for hip fracture patients. However
more studies need to be undertaken before it becomes a national hip fracture risk stratiﬁcation or audit
tool of choice.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fragility hip fractures among the elderly constitute a signiﬁcant
global public health problem. Risk scoring to identify high risk
patients is strongly encouraged [1]. It aims to provide prognostic
information based on available patient data. This in-turn allows:
(a) increased objectivity in patient outcome prediction, (b)
guidance on clinical decision making during perioperative period,
(c) better informed consent for patients undergoing hip fracture
surgery [2], and (d) treatment optimisation to improve outcome.
Various scoring tools exist and there is uncertainty as to the
most suitable tool for use in hip fracture. The ideal risk scoring tool
has the following attributes: simple; ease of use; reproducible;
accurate; reliable; objective and available to all patients [2]. The
extent to which current hip fracture scoring systems meet these
criteria is unclear. This study aims to describe the components,
likely clinical utility and degree of validation of published risk
scoring tools.
Materials and methods
We searched eight databases; AMED, CINHAL, Clinical Trials.-
gov, Cochrane, DARE, EMBASE, MEDLINE, and Web of Science. The
review considered all relevant published studies on development
and validation of risk stratiﬁcation tools in patients with fragility
hip fracture. Studies were considered using the recommended
standards guidelines for reporting systematic reviews of observa-
tion studies [3]. All relevant studies worldwide in any language
published from 1966 to the 30th of April 2015, inclusive were
included in the review. The search strategy is outlined as
supplementary data appendix 1.
Study selection and outcome deﬁnition
We deﬁned a risk stratiﬁcation tool as ‘‘a scoring system or
model used to predict or adjust for either mortality or morbidity
after surgery, and which contains at least two different risk
factors’’ [1]. Eligible studies were identiﬁed by title, abstract and
full-text screening independently by the authors and discrepan-
cies resolved by consensus. Manual hand searching of ﬁrst
generation reference lists was performed. Data extraction was
independently undertaken by TM and AM on pre-piloted database
forms. We extracted data for each study against the following four
facets of validity and reliability: (1) development of items:
development and validation samples in same or different cohorts;
random selection of samples; (2) process for validation: single
centre; multicentre; international; (3) metrics of discrimination:
AUROC/c-statistics; and (4) metrics of calibration: Hosmer–
Lemeshow or Pearson chi-square statistics. Studies were assessedfor methodological quality and risk of bias using Altman’s [4]
framework for assessing internal validity.
Data and statistical analysis
Calibration and discrimination are the two main performance
measures used to evaluate individual risk scoring tools. Discrimi-
nation was reported using either the AUROC or the concordance (c-
) statistic with AUROC of less than 0.7, 0.7–0.9 and greater than
0.9 considered to indicate poor, moderate and high tool perfor-
mance respectively [1]. As AUROC was not consistently reported,
the observed compared to expected outcome ratio (observed/
expected (O/E)), Spearman’s rank correlation and chi-squared test
were also used to evaluate risk scoring tool performance.
The agreement between observed and predicted outcomes
(calibration) was evaluated using Hosmer–Lemeshow or Pearson
chi-square statistics. P < 0.05 reﬂected evidence of lack of ﬁt [1].
Results
The search produced 15,620 articles, and 680 were eligible for
abstract screening (Fig. 1). Most studies considered at the abstract
stage, reported risks for sustaining hip fracture, rather than
outcome following hip fracture, and 12 studies were conference
abstract presentations with no full published papers and therefore
were excluded leaving 43 studies for full text analysis. Of the 43 full
text studies sought, 30 [5–34] met the inclusion criteria with
results presented with sufﬁcient data to evaluate the study
outcomes (Table 1). Thirteen full text studies [35–48] did not have
sufﬁcient qualitative or quantitative data relevant to this review,
and were excluded. All studies included in this review were cohort
studies.
Quality assessment
Quality assessment for eligible studies is outlined in
Table 1. Seven studies were multicentre with a maximum of nine
study sites in one study [24]. Selection bias was not observed in the
included studies, though ethnic origin was constrained by the
demographic of the study country. Heterogeneity among included
studies was observed in method of statistical analysis, variation in
time frame of outcome measurements, and in the number of
models assessed by individual articles.
Validation
Three forms of validation were observed across included
studies; (a) internal – validation in split sample of the same study
population as tool derivation cohort, (b) external – validation in
Fig. 1. Flow chart of results.
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institute and (c) temporal – validation in new cohort from
derivation study but same institution(s). Supplementary data
appendix 2 summarises data for commonly used tools and shows
how widely each risk stratiﬁcation tool has been validated and the
original tool development cohort.
Types of risk stratiﬁcation tools
A total of 25 risk stratiﬁcation tools (supplementary data
appendix 3) were reported among all the included studies. Ten of
these 24 risk scoring tools were considered in two or more studies
(supplementary data appendix 4). The O-POSSUM, NHFS, E-PASS,
CCI and ASA were reported in more than three studies each with a
total sample of 5975, 13 977, 5832, 6 230 456 and 5411 patients
respectively. The other ﬁve tools, score by Jiang et al., Risk Model
for Delirium (RD), P-POSSUM, Barthel Index and Mini Mental State
Examination (MMSE) were reported in two studies each.
Outcomes
The main outcomes (Table 2) were mortality, morbidity and
mobility. Timing of outcome measurement ranged from in-
hospital mortality or length of hospital stay to more than 1 year.
Twenty-six studies reported mortality as the main outcome. In-
hospital, 30 day and 1 year mortality ranged from 1.6% [25] to 9.7%
[8], 6.6% [26] to 10.9% [20], and 26% [12] to 30.8% [15] respectively.
Sixteen studies reported morbidity, which widely varied from
17.0% [24] to 49.6% [8].
Discrimination
The area under the receiver operating characteristic curve
(AUROC) was presented in 17 studies and ranged from 0.50 to0.87. Fifteen studies reported AUROC values for scoring systems of
>0.7. None of the studies reported AUROC values >0.90.
Calibration
Ten studies reported calibration. Eight calculated calibration
using Hosmer–Lemeshow test with P values ranging from 0.00015
[16] to 0.79 [29]. Two studies [14,18] reported whether the model
was of ‘good ﬁt’ or ‘poor ﬁt’ without further statistical presentation.
Calibration values for one study [22] were not presented in the
original paper, but were given by the authors in a subsequent letter
[49].
Risk stratiﬁcation tools published in more than one study
Preoperative scores
Three clinical scoring systems that use readily available pre-
operative data were validated in multiple studies; ASA [8,18,29],
CCI [7–10,12] and NHFS, [10,26–31].
American Society of Anesthesiologists physical score (ASA). The ASA is
widely used as a surrogate for operative risk and grades patients
according to their chronic physiological state. The three studies
which considered ASA found it to be of poor to moderate
discriminant accuracy (AUROC varying from 0.60 to 0.71).
Charlson Comorbidity Index (CCI). The CCI is a medical risk
prediction tool, which has been adapted for surgical risk
stratiﬁcation. All the studies reported moderate AUROC for CCI
on mortality (0.7–0.77) but poor prediction with regards to 90 days
mortality (0.59).
Nottingham Hip Fracture Score (NHFS). The NHFS is a combination
of seven independent predictors of mortality. AUROC values
Table 1
Characteristics of included studies.
Study ID Risk scoring model Timing Country Number
of
centres
Patients (n) Study
purpose
Validation
Cohort:
internal vs.
external vs.
temporal
Outcome End point
d – days
m – months
Subject
description
Selection
bias
Moerman [5] RD Prospective Netherlands 1 378 Validation Internal Morbidity Hospital
discharge
Y N
Vochteloo [6] RD Prospective Netherlands 1 378 Validation Internal Morbidity
mortality
Hospital
discharge
90 d
12 m
Y N
Neuhaus [7] CCI Retrospective USA National 6,137,665 Validation External Mortality Hospital
discharge
Y N
Burgos [8] ASA, CCI
POSSUM, Barthel
Index
Goldman Index
Prospective Spain 1 232 Validation external Morbidity
Ambulation
Mortality
Hospital
discharge
30 d
90 d
Y N
Toson [9] CCI Retrospective Australia 1 47,698 Validation External Mortality Hospital
discharge
30 d
12 m
Y N
Karres [10] Jiang et al., NHFS,
Holt et al.
E-PASS, CCI
O-POSSUM
Re´trospective Netherlands 1 1050 Validation External Mortality 30 d Y N
Dawe [11] Sernbo Score Prospective UK 1 259 Validation Internal Mortality 30 d
12 m
Y N
Radley [12] CCI (Romano
adaptation)
CCS, Iezzoni
Retrospective USA 1 43,811 Comparative External Mortality 12 m Y N
Bellelli [13] New predictive risk
score, MMSE, BMI
Barthel Index
Prospective Italy 1 398 Tool
development
Internal Ambulation
(mobility)
Hospital
discharge
>12 m
Y N
Vochteloo [14] DHP Prospective Netherlands 2 435 Validation External Ambulation
(mobility)
Hospital
discharge
Y N
Jiang [15] New Risk score Retrospective Canada 2 3981 Tool
development
Internal Mortality Hospital
discharge
12 m
Y N
Soderqvist [17] ASA
SPMSQ
Prospective Sweden 4 1944 Comparative
study
External Mortality Hospital
discharge
120 d
24 m
N N
Ramanathan [16] O-POSSUM Prospective UK 1 1164 Validation External Mortality 30 d Y N
van Zeeland [18] O-POSSUM
ASA
Prospective Netherlands 1 272 Validation External Morbidity
Ambulation
Mortality
Hospital
discharge
N N
Bonicoli [19] O-POSSUM
P-POSSUM
Prospective Italy 1 134 Comparative External Mortality
Morbidity
Hospital
discharge
N N
Wright [20] O-POSSUM Prospective UK 1 230 Validation External Mortality
Morbidity
30 d N N
Steinberg [21] O-POSSUM Retrospective Israel 1 1770 Validation External Mortality Hospital
discharge
Y N
Hirose [22] E-PASS
P-POSSUM
O-POSSUM
Retrospective Japan 8 722 Grp A
633 Grp B
Validation External Mortality
Morbidity
Hospital
discharge
30 d
N N
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T.C. Marufu et al. / Injury, Int. J. Care Injured 46 (2015) 2325–2334 2329reported in three studies 0.72 [29], 0.73 [31] and 0.77 [10] showing
this score to be a moderately discriminatory tool. Calibration is
adequate: the original single centre tool development reported
P = 0.79 (Hosmer–Lemeshow) [29] and multicentre validation
reported P > 0.1 [26] showing adequate ‘goodness-of-ﬁt’ on
performance of this model. One study [27] showed that increasing
NHFS was negatively correlated with eventual return-to-home
r2 = 0.949.
Physiological scores (models incorporating pre- and intra-operative
scores)
POSSUM discrimination (AUROC) ranges from 0.63 to 0.65 for
90 days mortality and ambulation, suggesting poor discrimination
[8]. The orthopaedic version (O-POSSUM) has AUROC values
ranging 0.62 [8] to 0.74 [21] for mortality, and 0.83 [18] for both
mortality and morbidity. However, calibration appeared poor with
the observed and expected ratio ranging from 0.12 to 1.19 [18]. The
P-POSSUM observed and expected ratio values had a wide range
0.15 [22] and 2.17 [19] for in hospital mortality.
Five studies on E-PASS, [10,22–25] reported their results in
various forms. AUROC 0.72 and calibration P = 0.103 [10] and O/E
values ranged from 0.55 to 1.59 [22]. Four studies observed a
signiﬁcant positive correlation between Physiological Risk Score
(PRS) and Comprehensive Risk Score (CRS) to measured outcomes
but there was no signiﬁcant correlation observed between the
surgical stress score (SSS) and outcomes. Cost of hospitalisation
was reported to be associated with SSS and CRS [23,25]. All other
risk models reported in two or less studies are detailed appendix 3.
Discussion
This study provides a comprehensive review of the current
evidence on a variety of risk stratiﬁcation tools used in hip fracture
patients. Of the 25 scoring systems identiﬁed, only ﬁve had been
evaluated in more than two studies, and four outside their original
centre. Of these ﬁve ASA does not perform well; despite its
simplicity [1] it does not appear to be robust enough in this
population. Each of the other four tools has arguments for and
against its clinical utility; e.g. tool availability and the objectivity of
its parameters. Some tools may be perceived as complex and less
likely to be part of daily routine use.
Simplicity and availability
The Nottingham Hip Fracture Score and (NHFS) and Charlson
Comorbidity Index (CCI) use readily available pre-operative data.
They both have reasonable, though not excellent, discriminant
characteristics for mortality and morbidity and have been
validated external to their original cohort.
The CCI uses well deﬁned comorbidities. It weights these based
on severity and assigns each individual an overall risk score
presenting the sum of their comorbidity weights [12]. It is a
moderately discriminant tool for in-hospital morbidity and 1 year
mortality. However calibration is not well described and this limits
its ability as an audit tool. Functional ability and confusion (as
opposed to dementia) which are known predictors of outcome
following hip fracture are not included.
The NHFS is a hip fracture speciﬁc score, which has been
validated for early hospital discharge [27], 30-day mortality [29] and
1 year mortality [28]. Its discriminant ability is moderate and has
reasonable calibration. All the required data items are routinely
collected. It uses the Abbreviated Mental Test Score (AMTS) as its
assessment for cognitive impairment which may not be so widely
used in countries outside the UK. There are currently no data on
regarding the interchangeability of screening tests for cognitive
impairment, such as MMSE or clock drawing, in this context.
Table 2
Outcomes.
Study ID Risk scoring
model
End point Morbidity (%)
(NR=not
recorded)
AUROC morbidity (95% CI) Mortality (%) Calibration (Hosmer–Lemeshow test)
(NR=not recorded)
AUROC mortality
(95% CI)
Moerman [5] RD Hospital discharge NR 0.73 (0.68–0.77) NR NR NR
Vochteloo [6] RD Hospital discharge 27 0.72(0.67–0.77) NR NR NR
Neuhaus [7] CCI Hospital discharge NR NR 9 NR CCI, ICD-9 adapted 0.767
CCI, age adjusted 0.766
CCI, updated 2011 0.768
Burgos [8] ASA
CCI
POSSUM
Barthel Index
Goldman Index
RISK-VAS
Hospital discharge
30 d
90 d
49.6 Hospital discharge:
RISK-VAS 0.833 (0.757–0.910),
Barthel 0.67 (0.565–0.780)
Goldman 0.652 (0.522–0.781),
POSSUM 0.726 (0.615–0.838)
CCI 0.707 (0.602–0.811), ASA 0.675
(0.571–0.778)
11.2 NR 90 d:
RISK-VAS 0.677 (0.545–0.809)
Barthel 0.689 (0.584–0.794)
Goldman 0.432 (0.315–0.548)
POSSUM 0.635 (0.518–0.751)
CCI 0.590 (0.482–0.698)
ASA 0.600 (0.488–0.711)
Toson [9] CCI Hospital discharge
30 d
12 m
NR NR 8.2
8.3
26.3
NR 0.72–0.76
0.72–0.75
0.69–0.75
Karres [10] Jiang et al.
NHFS
Holt et al.
E-PASS
CCI
O-POSSUM
Hospital discharge
30 d
NR NR 6.0
8.2
P=0.041
P=0.039
P=0.103
P=0.002
P=0.291
P=0.110
0.78 (0.73–0.83)
0.77 (0.72–0.82)
0.76 (0.71–0.81)
0.72 (0.67–0.77)
0.71 (0.65–0.77)
0.69 (0.63–0.74)
Dawe [11] Sernbo Score 30 d
12 m
NR NR NR NR 30 d: 0.71 (0.65–0.76)
12 m: 0.68 (0.59–0.75)
Radley [12] CCI (Romano
adaptation)
CCS
Iezzoni
12 m NR NR 26 Overall model
performance good
CCI 0.72
CCS 0.76
Iezzoni 0.73
Jiang [15] New risk score Hospital discharge
12 m
NR NR 6.3
30.8
P>0.50 goodness of ﬁt 0.82
0.74
Soderqvist
[17]
ASA
SPMSQ
Hospital discharge
120 d
24 m
NR NR 4
16
38
NR 24 m: age, gender ASA 0.71
24 m: age, gender, SPMSQ 0.70
Ramanathan
[16]
O-POSSUM 30 d NR NR 10 Poor ﬁt P<0.00015 0.62
van Zeeland
[18]
O-POSSUM
ASA
Hospital discharge NR O-POSSUM 0.83 (0.76–0.90) 9 Good for mortality
Poor for morbidity
O-POSSUM 0.83 (0.76–0.89)
ASA 0.76 (0.66–0.85)
Steinberg [21] O-POSSUM Hospital
discharge
NR NR NR NR 0.63 (0.58–0.68) model without
albumin levels
0.74 (0.65–0.83) model with
albumin level
Moppett [26] NHFS 30 d NR NR 6.6 P>0.1 NR
Maxwell [29] NHFS
ASA
Donati Score
30 d NR NR 10.2 0.79 NHFS 0.719 (SE0.018)
ASA 0.718 (SE 0.0163)
Donati Score 0.717(SE0.0184)
Krishnan [31] NHFS
Frailty index
(FI)
30 d NR LOS, 0.73 (0.64–0.82)
LOS, 0.82 (0.75–0.89)
NHFS <5, 1.6
NHFS 5, 10.4
Intermediate FI, 3.4
High FI, 17.2
NR
Albertson
[34]
FRAMO Index 24 m NR NR NR NR 0.75 (0.71–0.79)
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Studies with results presented as observed to expected ratios (O:E) and spearman’s rank correlation
Bellelli [13] O-POSSUM
P-POSSUM
Hospital discharge 49.25 POSSUM 1.1 9.7 NR POSSUM 0.81
P-POSSUM 2.17
Wright [20] O-POSSUM 30 d 41.3 O:E
0.95
10.9 NR O:E
1.19
Hirose [22] E-PASS
P-POSSUM
O-POSSUM
Hospital discharge
30 d
Grp A 17.2 Grp B
20.2
Grp A
Hospital discharge
Morbidity rates increased linearly
with CRS, P=0.17, P0.0001 and
PRS, P=0.17, P<0.0001, but not with
SSS, P=0.01, P=0.8
Grp A 1.7
Grp B 2.4
E-PASS in hospital (mortality 0.40,
morbidity 0.65) 30 d (mortality 0.48,
morbidity 0.35)
P-POSSUM in hospital (mortality 0.30)
O-POSSUM 30 d (mortality 0.24,
morbidity 0.11)
Grp A
Hospital discharge
Mortality rates correlated with
PRS, P=0.16, P<0.0001 and CRS
P=0.18, P<0.0001 but not with
SSS, P=0.01, P=0.8
Grp B
Hospital discharge
E-PASS 1.06
30d:
E-PASS 1.59
O-POSSUM 0.12
Grp B
Hospital discharge:
E-PASS 0.71, P-POSSUM 0.15
30 d:
E-PASS 0.55
O-POSSUM 0.12
Hirose [23] E-PASS Hospital discharge 18.4 Spearman correlation:
morbidity signiﬁcantly increased
with both the PRS (P=0.19,
P=0.0001) and CRS (P=0.21,
P<0.0001), but not with the SSS
(P=0.005, P=0.3)
The cost of hospital stay was
signiﬁcantly related to the SSS
(r=0.6, P<0.0001) and CRS (r=0.4,
P<0.0001) (Pearson’s correlation)
1.9% NR Spearman correlation:
mortality rates correlated with
PRS (P=0.19, P=0.0001) CRS
(P=0.21, P<0.0001) but not
with SSS (P=0.02, P=0.6)
Hirose [24] E-PASS Hospital discharge
12 m
Grp A 23.5, Grp
B 17.0
Grp A
Hospital discharge
Spearman correlation
In hospital morbidity correlated
with the SSS P=0.14, P=0.021, CRS
P=0.13, P=0.030, but not with the
PRS, P=0.09, P=0.08
Grp A 2.2
Grp B 2.0
Grp A 6.8
Grp B 9.8
NR Hospital discharge
Spearman correlation
In hospital mortality was
correlated with SSS P=14,
P=0.019, but not with PRS,
P=0.05, P=0.220 and CRS
P=0.001, P=0.494
Hirose [25] E-PASS Hospital discharge 20 Spearman correlation
Post-operative morbidity rates
increased linearly and correlated
signiﬁcantly with (preoperative risk
score (PRS)) P=0.16, P<0.0001)
(comprehensive risk score (CRS)
P=0.18, P<0.0001) but not surgical
stress score (SSS) P=0.06, P=0.07)
Cost of hospitalisation PRS (R=0.12,
P<0.0001) SSS (r=0.44, P<0.0001)
CRS (r=0.23, P<0.0001) (Pearson
correlation)
1.6 NR Spearman correlation
mortality rates correlated with
PRS (P=0.14, P=0.0001) CRS
(P=0.14, P=0.0001)but not with
SSS (P=0.03, P=0.4)
Moppett [27] NHFS Hospital discharge
30 d
12 m
NR Hospital discharge
Increasing NHFS was negatively
correlated with eventual return-to-
home (r2 =0.949), and with the
proportion of patients discharged
back to their own home at 7, 14 and
21 postoperative days respectively
(r2 = 0.84, 0.94, 0.96 respectively)
8.3
29.3
NR NR
Wiles [28] NHFS 30 d
12 m
NR NR 8.3
29.3
NR 30 d
survival was higher in the low
risk group 96.5% vs. 86.3%
(P<0.001)
12 m
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Table 2 (Continued )
Study ID Risk scoring
model
End point Morbidity (%)
(NR=not
recorded)
AUROC morbidity (95% CI) Mortality (%) Calibration (Hosmer–Lemeshow test)
(NR=not recorded)
AUROC mortality
(95% CI)
Rushton [30] NHFS 30 d NR NR 7.3 NR NR
Foss [33] CAS
NMS
Hospital discharge
30 d
21.6 Chi-squared values for CAS vs. NMS
were 60.3, 20.2 for the risk of post-
operative morbidity and 97.6,
68.3 for the association with patient
discharge to own home
30 d: 10.3 Chi-squared values for CAS vs.
NMS were 49.1, 20.0 for the
association with 30 days
mortality
Studies presenting ambulation as the outcome
Burgos [8] ASA
CCI
POSSUM
Barthel Index
Goldman Index
RISK-VAS
Hospital discharge
30 d
90 d
NR 30 d:
RISK-VAS 0.700, Barthel 0.737
90 d:
RISK-VAS 0.700 (0.628–0.771)
Barthel 0.737 (0.672–0.801)
Goldman 0.567 (0.491–0.643)
POSSUM 0.646 (0.573–0.718)
CCI 0.634 (0.563–0.706)
ASA 0.624 (0.551–0.698)
NR NR
Bellelli [13] New predictive
risk score
MMSE
BMI
Barthel Index
Hospital discharge
>12 m
NR Hospital discharge: Walking
independently
New risk score 0.8593, MMSE 0.7685
BMI 0.4989, Barthel Index 0.8700
12 m: Walking independently
New risk score 0.75, MMSE 0.7267
BMI 0.5209, Barthel Index 0.7344
NR NR
Vochteloo
[14]
DHP Hospital discharge NR Discharge location
Delft Cohort (0.84, 0.79–0.88)
Groningen Cohort (0.75, 0.66–0.82)
NR NR
Hirose [24] E-PASS Hospital discharge
12 m
NR NR NR Grp A Hospital discharge
Predictor variables of walking ability at
discharge was signiﬁcantly correlated
with PRS P=0.34, P<0.001, CRS, P=0.33,
P<0.001 not with SSS P=0.001,
P=0.495
12 m:
walking ability at 1 year was
signiﬁcantly correlated with, PRS,
P=0.41, P<0.001, CRS, P=0.40,
P<0.001 not with SSS P=0.05,
P=0.236
Grp B Hospital discharge
the predicted walking ability calculated
by the logarithm was signiﬁcantly
correlated with the actual ability at
discharge P=0.60, P<0.001 and at
12 m:
after surgery P=0.65, P<0.001
Adunsky [32] MMSE
CDT
Cognitive-FIM
Hospital discharge NR NR P<0.001 Pearson correlation between the three
cognitive tests resulted in values ranging
from 0.607 to 0.732
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and limitations. The O-POSSUM is the orthopaedic version of the
original POSSUM model. Both models use weighted pre and
intraoperative data; hence they cannot be used for preoperative
risk prediction. They are also perhaps more complex to score with
several variables; the O-POSSUM has 18 variables. E-PASS,
O-POSSUM, CCI and NHFS have all been validated internationally
[10].
Reported outcomes
Outcomes in the included studies were heavily biased towards
mortality. It is a dichotomous variable that is clearly undesirable,
objective, clinically important and easy to measure [50], and has
dependence on the time frame of measurement. Mortality rates at
ﬁxed time periods were easily comparable between studies.
Morbidity occurred frequently in all studies with a reported
incidence of 17–49.6%. Heterogeneity in morbidity deﬁnition and
classiﬁcation has been observed among included studies. Most
studies did not look at functional outcomes.
Prognostic variables
The range of prognostic variables used by the risk stratiﬁcation
tools is summarised in appendix 5. The items in the scores have
face validity: they are all known independent predictors of, or
surrogates for, outcome. However, some of these may be
somewhat subjective. There are other predictive variables not
currently included in the commonly used models (for example, red
cell width distribution on admission [51], albumin [21] levels, and
some inﬂammatory markers [52,53]) that may merit future
consideration.
Study strengths and limitations
We conducted a comprehensive search strategy with strict
adherence to Centre for Reviews and Dissemination (CRD) [3]
systematic review guidance. Search strategy, data extraction and
quality assessment was performed independently by the authors
and ﬁndings were conﬁrmed within the team.
However the review has limitations. Heterogeneity observed in
this review, within and among studies, could also have inﬂuenced
our results. There was variation in outcome analysis and outcome
measures. Five different statistical measures were used for
predictive ability of individual risk score tools, AUROC, r2,
correlation coefﬁcient, O:E and percentages. This was felt
necessary to include all high quality studies, for a comprehensive
over view of scoring tools available. Unfortunately this also
reduced our ability to perform appropriate comparison among all
the models presented. This lack of uniformity could affect clarity of
which risk score is superior to the other.
Conclusions and future work
The use of risk prediction scores during the perioperative
period has been accepted by clinicians as the norm, inﬂuencing
important informed decision making, to help optimise individual
patients’ care and to support audit and service improvement.
However, the predictive accuracy of risk scores could be more
robust and multinational validation is currently lacking. This
review has highlighted both strengths and weaknesses of the
currently available risk scoring models. This study noted that all
outcome measures outlined were medically oriented. Future
work could consider the psychological and social dimensional
factors that impede early patient discharge in this patient
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